Nothing Special   »   [go: up one dir, main page]

Eliana et al., 2006 - Google Patents

EVALUATION OF INFLIXIMAB IN THE TREATMENT OF ACTIVE JUVENILE RHEUMATOID ARTHRITIS (JRA): 43

Eliana et al., 2006

Document ID
844777230480168967
Author
Eliana G
Amparo E
Ferrandiz M
Publication year
Publication venue
JCR: Journal of Clinical Rheumatology

External Links

Snippet

Background: Therapy with anti-TNF is indicated in nonresponsive JRA. We reported the infliximab experience in JRA. Purpose: To evaluate the efficacy and safety of Infliximab in our patients with JRA non responsive to methotrexate (MTX). Methods: We evaluated 8 JRA …
Continue reading at journals.lww.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Micro-organisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Similar Documents

Publication Publication Date Title
Cerda-Téllez et al. INTRAVENOUS IMMUNOGLOBULIN (IVIG) TREATMENT IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES (IIM): 46
Cusa et al. Correlation Between the Auscan Index (Ai) and Strength, Dexterity and Function Tests in Patients With Primary Osteoarthritis of the Hand (Poah): 75
Eliana et al. EVALUATION OF INFLIXIMAB IN THE TREATMENT OF ACTIVE JUVENILE RHEUMATOID ARTHRITIS (JRA): 43
Amparo et al. EFFICACY OF ETANERCEPT (ETN) IN JUVENILE RHEUMATOID ARTHRITIS (JRA): 41
Puertas et al. CASE REPORT: REMISSION OF THE ADULT ONSET STILL DISEASE, IN A YOUNG MALE PATIENT TREATED WITH ETANERCEPT: 44
Ralha et al. EFFICACY AND TOLERABILITY OF CELECOXIB 200 mG BID VERSUS DICLOFENAC 75 mG BID IN ACUTE LOW BACK PAIN: 62
Bori-Segura et al. ANALYSIS OF DIFFERENT ASSAYS ON BASIC AND CLINICAL EXPERIENCE WITH ACEMETACIN IN MEXICO: 54
Vetrila SEASON AFFECTS IN THE IDIOPATHIC INFLAMMATORY MYOPATHIES: 51
Eliana et al. SECONDARY AMYLOIDOSIS (AA) IN JUVENILE RHEUMATOID ARTHRITIS (JRA): 42
Mantilla et al. PREVALENCE OF THE OBESITY IN PATIENTS WITH OSTEOARTHRITIS: 72
Mendoza et al. PAIN/FUNCTIONAL LIMITATION RELATIONSHIP IN PATIENTS WITH KNEE OA: THE INFLUENCE OF AGING: 74
Ibáñez et al. ANALYSIS OF CLINICAL CHARACTERISTICS OF JUVENILE RHEUMATOID ARTHRITIS IN THE INSTITUTO ESPECIALIZADO DE SALUD DEL NIÑO: 40
Jáuregui et al. IMMUNOGENICITY INDUCED BY BIOLOGIC THERAPY IN A COLOMBIAN POPULATION: 61
Mulhern et al. Efficacy of Celecoxib in Knee Osteoarthritis Unresponsive to Naproxen and Ibuprofen: 79
Caggiani et al. DERMATOMIOSITIS JUVENIL: 48
Julio et al. PROLONGED REMISSION OF JUVENILE ARTHRITIS WITH PROSORBA COLUMN TREATMENT: 38
Finger et al. RITUXIMAB IN REFRACTORY AUTOIMMUNE DISEASES: BRAZILIAN EXPERIENCE WITH 32 PATIENTS (2002–2006): 55
Salazar et al. HAND OSTEOARTHRITIS POST-MECHANICAL AND REPETITIVE JOINT TRAUMA IN MANUAL WORKERS: CONSTRUCTION WORKERS IN AREQUIPA CITY: 76
Ramos-Remus et al. ELEVATED LIVER ENZYMES IN RHEUMATIC DISEASES IN TREATMENT WITH MTX. RELATION WITH BLOOD SAMPLE DAY?: 63
Möller et al. USE OF SONOGRAPHY TO EVALUATE THE PRESENCE OF JOINT EFFUSION IN GONARTHROSIS AND ITS CORRELATION WITH PAIN, FUNCTIONAL CAPACITY AND DEGREE OF RADIOLOGICAL INVOLVEMENT: 74B
Abdel-Majid et al. AGE-RELATED EXPRESSION OF IGF-1 BINDING SITES ON RAT ARTICULAR CHONDROCYTES IN MONOLAYER CULTURE: 69
Eduardo et al. RELATIONSHIPS OF PATIENT'S PERCEPTION OF DISEASE, SELF-REPORTED WALKING TOLERANCE AND DURATION OF DISEASE TO PAIN AND FUNCTIONAL LIMITATION IN PATIENTS WITH KNEE OA: 77
Cefferino et al. THE ROLE OF WORK-RELATED FACTORS ON PAIN AND FUNCTIONAL LIMITATION IN PATIENTS WITH SYMPTOMATIC KNEE OA: 73
Benites-Godínez et al. IS THERE A DIFFERENCE IN THE FREQUENCY OF ADVERSE DRUG EVENTS IN DIFFERENT RHEUMATIC DISEASES?: 53
Calvo et al. CLINICAL MANIFESTATIONS ASSOCIATED TO ANTI-RO/SSA ANTIBODY IN SYSTEMIC LUPUS ERYTHEMATOSUS AND SJÖGREN′ S SYNDROME DIAGNOSED PATIENTS: 34